MIAMI--(BUSINESS WIRE)--Vigilant Biosciences, Inc. (“Vigilant”), developer of the “rinse and spit” test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.
Help employers find you! Check out all the jobs and post your resume.